Aymeric Le Chatelier
Chief Financial Officer
Replay available
Ipsen Sa S/Adr (OTC: IPSEY) Q4 2025 earnings conference call, held 2026-02-12. Replay captured from the company's public earnings webcast.

Chief Financial Officer
Chief Executive Officer
Analyst at Barclays
Analyst at UBS
Analyst at Rothschild & Co
Analyst at JP Morgan
Analyst at BNP Paribas
Analyst at Jefferies
Good day and thank you for standing by. Welcome to IPSEN's conference call and webcast on full year 2025 results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one and one again. Please, the advice of today's conference is being recorded. I will now like to hand the conference over to your speaker today, David Lowe, Ibsen CEO. Please go ahead. Thank you, operator, and hello, everyone. I'm delighted to welcome you to our presentation this afternoon, which can also be found on Ibsen.com. I want to use the time we have together to focus on the progress Ibsen delivered in 2025, and on the future opportunities and platforms for growth. Please turn to slide two. Please take note of our forward-looking statements, which outline the routine risks and uncertainties contained within this presentation. Also, all of my comments on growth will be based on constant exchange rates. Please turn to slide three. I'm going to take you through the presentation of our latest business update, followed by our CFO, Aymeric Le Chatelier, who will take you through the financials, and finally, I will provide an R&D update. At the end of the presentation, we will open the Q&A session. Let's begin by looking at today's highlights. Please turn to slide four. Turn to slide five. Today's headlines illustrate how we are continuing to deliver strong and sustainable growth. In 2025, total sales grew double digits by 10.9%. a performance driven mostly by the strong performance of our portfolio, excluding somatoli...